Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Patient-Led Multi-System Biomarker Tracking in Long COVID
Mapping Vascular, Immune, and Neurological Markers Over Three Years in a 60-Year-Old Male with Post-Acute Sequelae of SARS-CoV-2 (PASC): A Viewpoint
Stephen Merryman
ABSTRACT
Long COVID / post-acute sequelae of SARS-CoV-2 infection (PASC) develops in at least 10% of acute SARS-CoV-2 infections and is estimated to affect more than 65 million people worldwide [1]. The condition currently lacks accepted diagnostic biomarkers, effective therapeutic options, and, for many patients, any meaningful clinical support. This Viewpoint describes the methodology and utility of a single patient systematically tracking multi-system biomarkers including vascular, immune, and neurological biomarkers, over approximately three years to map his own condition, and reflects on what longitudinal, patient-generated data can and cannot reveal about an individual disease course.
Citation
Please cite as:
Merryman S
Patient-Led Multi-System Biomarker Tracking in Long COVID
Mapping Vascular, Immune, and Neurological Markers Over Three Years in a 60-Year-Old Male with Post-Acute Sequelae of SARS-CoV-2 (PASC): A Viewpoint